One of the biggest charges levied against unicorn science startup Theranos is that its ground-breaking technology — which supposedly requires a fractional amount of blood — is neither reliable nor accurate compared to traditional blood tests. And in the first independent study published about the techniques, those critics might be onto something. The study, conducted by the Icahn School of Medicine at Mount Sinai in New York, tested 60 adults to compare uncertainty and accuracy across 22 common clinical lab tests offered by Theranos and its more traditional competitors, Quest and LabCorp. In the study, Theranos’ results were routinely higher — going above normal…
This story continues at The Next Web
No comments:
Post a Comment